Clinical Trial Update: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating TAK-755 for congenital thrombotic thrombocytopenic purpura is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• TAK-755

Snippet

Sponsor: Takeda | Conditions: Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | Status: ACTIVE_NOT_RECRUITING